AK Jain, ED, Ipca Laboratories in an interview with CNBC-TV18 said that the company has projected normal growth of around 18-20% for the whole year. But if it receives the much awaited USFDA approval then it can register much higher growth ahead.
first published: May 25, 2011 01:26 pm
A collection of the most-viewed Moneycontrol videos.
Nifty Slips Over 150 Points From Day's High But Gains For 6th Day| IT Stocks Surge|Closing Bell Live
Jigar Mistry flags potential risk to markets and what investors need to be cautious about
Will Nifty Clinch All-Time High As GIFT Nifty Signals Big Gap Up? HUL Q2 Today| Opening Bell Live
EU Ramps Up Ukraine Aid, Tomahawk Missiles as Trump-Putin Ceasefire Talks Risk Donbas Territory Loss
